Is Candel Therapeutics Stock a Good Investment?
Candel Therapeutics Investment Advice | CADL |
- Examine Candel Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Candel Therapeutics' leadership team and their track record. Good management can help Candel Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Candel Therapeutics' business and its evolving consumer preferences.
- Compare Candel Therapeutics' performance and market position to its competitors. Analyze how Candel Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Candel Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Candel Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Candel Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Candel Therapeutics is a good investment.
Sell | Buy |
Hold
Market Performance | Very Weak | Details | |
Volatility | Moderately volatile | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Sell | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Candel Therapeutics Stock
Researching Candel Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 30.0% of the company shares are held by company insiders. The company recorded a loss per share of 1.73. Candel Therapeutics had not issued any dividends in recent years.
To determine if Candel Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Candel Therapeutics' research are outlined below:
| Candel Therapeutics generated a negative expected return over the last 90 days | |
| Candel Therapeutics has high historical volatility and very poor performance | |
| Candel Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 31 K. Net Loss for the year was (37.94 M) with loss before overhead, payroll, taxes, and interest of (20.66 M). | |
| Candel Therapeutics currently holds about 86.78 M in cash with (34.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.0. | |
| Candel Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 30.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Disposition of 20000 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 4.97 subject to Rule 16b-3 |
Candel Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Candel Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Candel Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Candel Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Candel Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-11-12 | 2021-09-30 | -0.29 | -0.26 | 0.03 | 10 | ||
2023-08-10 | 2023-06-30 | -0.3 | -0.34 | -0.04 | 13 | ||
2023-05-11 | 2023-03-31 | -0.35 | -0.3 | 0.05 | 14 | ||
2022-11-10 | 2022-09-30 | -0.35 | -0.3 | 0.05 | 14 | ||
2022-08-05 | 2022-06-30 | -0.41 | -0.32 | 0.09 | 21 | ||
2023-11-09 | 2023-09-30 | -0.19 | -0.31 | -0.12 | 63 | ||
2023-03-30 | 2022-12-31 | -0.31 | -0.18 | 0.13 | 41 | ||
2021-09-08 | 2021-06-30 | -0.12 | -0.31 | -0.19 | 158 |
Know Candel Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Candel Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Candel Therapeutics backward and forwards among themselves. Candel Therapeutics' institutional investor refers to the entity that pools money to purchase Candel Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bank Of New York Mellon Corp | 2024-06-30 | 54.4 K | Bank Of America Corp | 2024-06-30 | 54.4 K | Charles Schwab Investment Management Inc | 2024-09-30 | 46.8 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 38.9 K | Advisor Group Holdings, Inc. | 2024-06-30 | 25.8 K | Rhumbline Advisers | 2024-06-30 | 23 K | Virtu Financial Llc | 2024-06-30 | 22.6 K | Vontobel Holding Ltd. | 2024-06-30 | 22 K | Jpmorgan Chase & Co | 2024-06-30 | 19.4 K | Northpond Ventures, Llc | 2024-09-30 | 1.9 M | Vanguard Group Inc | 2024-09-30 | 946.3 K |
Candel Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 134.29 M.Market Cap |
|
Candel Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.92) | (0.97) | |
| Return On Capital Employed | (1.42) | (1.35) | |
| Return On Assets | (0.92) | (0.97) | |
| Return On Equity | (2.98) | (2.83) |
Determining Candel Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Candel Therapeutics is a good buy. For example, gross profit margin measures Candel Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Candel Therapeutics' profitability and make more informed investment decisions.
Evaluate Candel Therapeutics' management efficiency
Candel Therapeutics has return on total asset (ROA) of (0.5231) % which means that it has lost $0.5231 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.8068) %, meaning that it created substantial loss on money invested by shareholders. Candel Therapeutics' management efficiency ratios could be used to measure how well Candel Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.97. Return On Capital Employed is expected to rise to -1.35 this year. At this time, Candel Therapeutics' Debt To Assets are quite stable compared to the past year. Asset Turnover is expected to rise to 0 this year, although the value of Non Currrent Assets Other will most likely fall to about 312.6 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.44 | 0.52 | |
| Tangible Book Value Per Share | 0.44 | 0.53 | |
| Enterprise Value Over EBITDA | (0.80) | (0.84) | |
| Price Book Value Ratio | 3.34 | 3.50 | |
| Enterprise Value Multiple | (0.80) | (0.84) | |
| Price Fair Value | 3.34 | 3.50 | |
| Enterprise Value | 29.9 M | 28.4 M |
Management at Candel Therapeutics focuses on leveraging technology and optimizing operations. We evaluate the impact of these focuses on the company's financial health and stock performance.
Beta (0.87) |
Basic technical analysis of Candel Stock
As of the 29th of November, Candel Therapeutics shows the Standard Deviation of 4.75, risk adjusted performance of (0.02), and Mean Deviation of 3.31. Candel Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Candel Therapeutics variance, maximum drawdown, as well as the relationship between the Maximum Drawdown and skewness to decide if Candel Therapeutics is priced correctly, providing market reflects its regular price of 4.71 per share. Given that Candel Therapeutics has information ratio of (0.06), we suggest you to validate Candel Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.Candel Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Candel Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Candel Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Candel Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Candel Therapeutics' Outstanding Corporate Bonds
Candel Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Candel Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Candel bonds can be classified according to their maturity, which is the date when Candel Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View |
Understand Candel Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Candel Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.1) | |||
| Mean Deviation | 3.31 | |||
| Coefficient Of Variation | (3,098) | |||
| Standard Deviation | 4.75 | |||
| Variance | 22.6 | |||
| Information Ratio | (0.06) | |||
| Jensen Alpha | (0.34) | |||
| Total Risk Alpha | (0.88) | |||
| Treynor Ratio | (0.11) | |||
| Maximum Drawdown | 26.28 | |||
| Value At Risk | (5.78) | |||
| Potential Upside | 6.7 | |||
| Skewness | 1.52 | |||
| Kurtosis | 6.14 |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.1) | |||
| Mean Deviation | 3.31 | |||
| Coefficient Of Variation | (3,098) | |||
| Standard Deviation | 4.75 | |||
| Variance | 22.6 | |||
| Information Ratio | (0.06) | |||
| Jensen Alpha | (0.34) | |||
| Total Risk Alpha | (0.88) | |||
| Treynor Ratio | (0.11) | |||
| Maximum Drawdown | 26.28 | |||
| Value At Risk | (5.78) | |||
| Potential Upside | 6.7 | |||
| Skewness | 1.52 | |||
| Kurtosis | 6.14 |
Consider Candel Therapeutics' intraday indicators
Candel Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Candel Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 0.0956 | |||
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 4.78 | |||
| Day Typical Price | 4.76 | |||
| Market Facilitation Index | 0.48 | |||
| Price Action Indicator | (0.07) | |||
| Relative Strength Index | 19.59 |
Candel Therapeutics Corporate Filings
F4 | 27th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 14th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 24th of May 2024 Other Reports | ViewVerify | |
10K | 25th of April 2024 An amendment to a previously filed Form 10-K | ViewVerify |
Candel Stock media impact
Far too much social signal, news, headlines, and media speculation about Candel Therapeutics that are available to investors today. That information is available publicly through Candel media outlets and privately through word of mouth or via Candel internal channels. However, regardless of the origin, that massive amount of Candel data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Candel Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Candel Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Candel Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Candel Therapeutics alpha.
Candel Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Candel Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Candel Therapeutics Corporate Management
| Francesca MD | Chief Officer | Profile | |
| LLM JD | Chief Officer | Profile | |
| Nathan Caffo | Chief Officer | Profile | |
| MS MD | Chief Officer | Profile | |
| FMEDSCI MD | CEO Pres | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Candel Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For more information on how to buy Candel Stock please use our How to buy in Candel Stock guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Candel Therapeutics. If investors know Candel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Candel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.73) | Revenue Per Share 0.001 | Return On Assets (0.52) | Return On Equity (4.81) |
The market value of Candel Therapeutics is measured differently than its book value, which is the value of Candel that is recorded on the company's balance sheet. Investors also form their own opinion of Candel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Candel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Candel Therapeutics' market value can be influenced by many factors that don't directly affect Candel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Candel Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Candel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Candel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.